NCTR appointment
This article was originally published in The Rose Sheet
Executive Summary
William Slikker, Jr., PhD, is appointed acting director of FDA's National Center for Toxicological Research, replacing Dan Casciano, PhD, who is moving to the private sector after serving in the role for more than six years, FDA announces Jan. 3. Slikker most recently worked as NCTR's deputy center director for research and is a "recognized leader in the field of toxicology, an accomplished scientist and educator, and a strong champion of NCTR's research program," agency notes...
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.